Brief: Rigel Pharmaceuticals Acquires U.S. Rights To GAVRETO

Rigel Pharmaceuticals

22/02/2024 14:44

Feb 22 (Reuters) - Rigel Pharmaceuticals Inc  RIGL.O :
    * RIGEL PHARMACEUTICALS ACQUIRES U.S. RIGHTS TO GAVRETO®
    * RIGEL PHARMACEUTICALS INC - BLUEPRINT WILL RECEIVE A
PURCHASE
PRICE OF $15.0 MILLION
    * RIGEL PHARMACEUTICALS INC - RIGEL EXPECTS TO COMPLETE
TRANSITION
OF ASSET AND START RECOGNIZING PRODUCT SALES IN Q3 OF 2024
    * RIGEL PHARMACEUTICALS INC - BLUEPRINT IS ALSO ELIGIBLE TO
RECEIVE UP TO $97.5 MILLION IN FUTURE COMMERCIAL MILESTONE
PAYMENTS
    * RIGEL PHARMACEUTICALS : PATENTS THAT HAVE ISSUED OR ARE
EXPECTED
TO ISSUE COVERING GAVRETO WILL HAVE STATUTORY EXPIRATION DATES
BETWEEN 2036 AND 2041
    * RIGEL PHARMACEUTICALS INC: EXPECTS TO COMPLETE TRANSITION
OF
ASSET AND START RECOGNIZING PRODUCT SALES IN Q3 OF 2024

Source text for Eikon:  ID:nPn9GW2rSa 
Further company coverage:  RIGL.O 

 ((Reuters.Briefs@thomsonreuters.com;))